Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia-Reference-Cited by-同舟云学术

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia

Published:2019-05-29 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Märklin Melanie,Hagelstein Ilona,Koerner Samuel P.,Rothfelder Kathrin,Pfluegler Martin S.,Schumacher Andreas,Grosse-Hovest Ludger,Jung Gundram,Salih Helmut R.

Funder

Deutsche Forschungsgemeinschaft

Wilhelm Sander-Striftung

Deutsche Krebshilfe

Fortüne Junior Grant

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0606-0.pdf

Reference47 articles.

1. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70(11):1445–76.

2. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9(1):16–32.

3. Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol. 2013;4:76.

4. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–10.

5. Raulet DH, Gasser S, Gowen BG, Deng WW, Jung HY. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol, Vol 31. 2013;31:413–441.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Schisandrol B inhibits calcification of aortic valve by targeting p53 related inflammatory and senescence;Biomedicine & Pharmacotherapy;2024-09

2. Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells;OncoImmunology;2024-07-27

3. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells;Journal for ImmunoTherapy of Cancer;2024-05

4. Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody;Blood Cancer Journal;2024-04-18

5. Enhancing cancer immunotherapy with Anti-NKG2D/IL-15(N72D)/Sushi fusion protein: Targeting cytotoxic immune cells and boosting IL-15 efficacy;Cytokine;2024-04